SCHEMBL1065699

SCHEMBL1065699

O=S(=O)(N1C[CH]CCC1)N1CCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
TSHR P16473 3/20 0.52
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 6/20 0.36
MEN1 O00255 3/20 0.36
LMNA P02545 1/20 0.36
CA12 O43570 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
MAPT P10636 2/20 0.33
HTT P42858 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
HPGD P15428 1/20 0.32
GAA P10253 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1066839 0.91 KMT2A (0.52) KMT2ATSHRPOLBSMN1; SMN2L3MBTL1
SCHEMBL9988709 0.79 CA1 (0.50) KMT2ATSHRPOLBCA1CA2
SCHEMBL771276 0.77 KMT2A (0.35) KMT2ATSHRPOLBSMN1; SMN2ALDH1A1
SCHEMBL5314300 0.77 KMT2A (0.81) KMT2ATSHRPOLBSMN1; SMN2L3MBTL1
SCHEMBL1069094 0.76 KMT2A (0.33) KMT2ATSHRPOLBSMN1; SMN2L3MBTL1
SCHEMBL9987867 0.74 EPHX2 (0.34) KMT2APOLBMEN1CA1CA2
SCHEMBL9988905 0.72 FKBP1A (0.33)
SCHEMBL1067872 0.72 EPHX2 (0.34) KMT2AMEN1LMNA
SCHEMBL1068447 0.72 GAA (0.57) KMT2ASMN1; SMN2L3MBTL1KDM4EALDH1A1
SCHEMBL1546827 0.71 POLB (0.87) KMT2ATSHRPOLBSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4613157-B2 2011-01-12 JP claimed
US-20090176307-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-07-09 US claimed
US-7491826-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2009-02-17 US claimed
US-7399866-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2008-07-15 US claimed
EP-1615878-A4 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2007-09-19 EP claimed
US-20070066626-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2007-03-22 US claimed
US-20060241110-A1 Compounds, compositions, and methods CYTOKINETICS, INCORPORATED 2006-10-26 US claimed
JP-2006515884-A 2006-06-08 JP claimed
EP-1615878-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2006-01-18 EP claimed
US-20050159416-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2005-07-21 US claimed
WO-2004064730-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2004-08-05 WO claimed
EP-2397462-A2 Compounds, compositions and methods of treatment for heart failure Cytokinetics, Inc. (US) 2011-12-21 EP disclosed
US-7910743-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-03-22 US disclosed
US-20090324511-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-12-31 US disclosed
US-20090176307-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-07-09 US disclosed
US-20070066626-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2007-03-22 US disclosed
US-20060241110-A1 Compounds, compositions, and methods CYTOKINETICS, INCORPORATED 2006-10-26 US disclosed
EP-1615878-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2006-01-18 EP disclosed
US-20050159416-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2005-07-21 US disclosed
WO-2004064730-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324511-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 KMT2A 4396/4885TSHR 4548/4885POLB 3536/4885
US-20060241110-A1 Compounds, compositions, and methods TNNI3, TNNT2, TNNC1 KMT2A 4398/4885TSHR 4482/4885POLB 3797/4885
US-20070066626-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KMT2A 4396/4885TSHR 4548/4885POLB 3536/4885
US-20050159416-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KMT2A 4396/4885TSHR 4548/4885POLB 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.